Equillium (EQ) Stock Price, News & Analysis

Company Overview

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Key Stats

• Today's Range: $0.32 to $0.34
• 50-Day Range: $0.29 to $0.46
• 52-Week Range: $0.27 to $1.50
• Volume: 40,195 shs
• Average Volume: 438,426 shs
• Market Capitalization: $11.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Equillium Stock Analysis - MarketRank™

Equillium scored higher than 37% of companies evaluated by MarketBeat, and ranked 1825th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Equillium has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Equillium has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Equillium are expected to decrease in the coming year, from $0.14 to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Equillium is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Equillium is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Equillium has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.89% of the float of Equillium has been sold short.

Short Interest Ratio / Days to Cover

Equillium has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Equillium has recently increased by 2,256.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Equillium does not currently pay a dividend.

Dividend Growth

Equillium does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.89% of the float of Equillium has been sold short.

Short Interest Ratio / Days to Cover

Equillium has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Equillium has recently increased by 2,256.26%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for EQ on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Equillium to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Equillium insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.60% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 27.05% of the stock of Equillium is held by institutions.

EQ Stock Analysis - Frequently Asked Questions

How have EQ shares performed this year?

Equillium's stock was trading at $0.7482 on January 1st, 2025. Since then, EQ stock has decreased by 56.3% and is now trading at $0.3270.

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) announced its quarterly earnings results on Thursday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.06. The company earned $4.39 million during the quarter. Equillium had a negative trailing twelve-month return on equity of 74.34% and a negative net margin of 19.62%.

When did Equillium IPO?

Equillium (EQ) raised $70 million in an initial public offering on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.

How do I buy shares of Equillium?

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Equillium own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Equillium investors own include NVIDIA (NVDA), Meta Platforms (META), Bank of America (BAC), Advanced Micro Devices (AMD), AbbVie (ABBV), Tilray Brands (TLRY) and Carnival (CCL).

Company Calendar

• Last Earnings: 3/27/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EQ
• CIK: 1746466
• Web: equilliumbio.com
• Phone: (858) 240-1200
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +817.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 2.34
• P/E Growth: N/A
• Net Income: -$8.07 million
• Net Margins: -19.62%
• Pretax Margin: -44.81%
• Return on Equity: -74.34%
• Return on Assets: -46.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.70
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: $41.10 million
• Price / Sales: 0.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 35,720,000
• Free Float: 24,432,000
• Market Cap: $11.68 million
• Optionable: Not Optionable
• Beta: 1.86